Drug intelligence / Profile preview

melphalan + eribulin

Development stage
Unknown
Lead developer
Eisai
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

**Melphalan + eribulin** is an investigational combination of two chemotherapeutic agents: melphalan, a bifunctional alkylating agent of the nitrogen mustard class, and eribulin, a non-taxane microtubule dynamics inhibitor and synthetic analog of halichondrin B. - **Melphalan** works by alkylating DNA and RNA, leading to crosslinking, inhibition of DNA replication and transcription, and subsequent cell death in both dividing and non-dividing tumor cells[5][6]. - **Eribulin** inhibits microtubule polymerization by binding tubulin at a unique site, suppressing microtubule growth and sequestering tubulin into nonfunctional aggregates, thereby inducing irreversible mitotic block (G2-M phase arrest) and apoptosis[1][2]. Both drugs have shown activity in various malignancies and, while combination studies are documented with other agents, there is no documented evidence of clinical development or trials for the exact combination "melphalan + eribulin" as of September 2025[1][2][5].

Brand names
Phelinun
Other names
melphalaneribulin mesylatemelphalan + eribulin
02

Targets

DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on melphalan + eribulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on melphalan + eribulin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call